Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Summary

Participation Requirements

Description

PRIMARY OBJECTIVES: I. To evaluate the feasibility of incorporating stereotactic body radiation therapy (SBRT) as a component of definitive local treatment for oligometastatic renal cell carcinoma (RCC). II. To estimate the 12-month progression free survival (PFS) rate after study enrollment utilizi...

PRIMARY OBJECTIVES: I. To evaluate the feasibility of incorporating stereotactic body radiation therapy (SBRT) as a component of definitive local treatment for oligometastatic renal cell carcinoma (RCC). II. To estimate the 12-month progression free survival (PFS) rate after study enrollment utilizing a strategy of definitive local treatment to all sites of disease in oligometastatic RCC as measured by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). SECONDARY OBJECTIVES: I. To determine the effect of SBRT on cellular replication, measured by ki-67 staining. II. To determine the systemic therapy free survival at 12 months. III. To estimate the overall survival at 12 months after study enrollment. IV. To estimate the freedom from new lesion development at 12 months. V. To determine the treatment related toxicities associated with SBRT as part of definitive local therapy for oligometastatic RCC. OUTLINE: Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist. After completion of study treatment, patients are followed up at 6 and 12 weeks, and then every 18 weeks for 1 year.

Tracking Information